Patent: 7,767,429

✉ Email this page to a colleague

Summary for Patent: 7,767,429

Title:	Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
Abstract:	The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP\'s), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
Inventor(s):	Bookbinder; Louis H. (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Del Mar, CA)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	10/795,095
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,767,429
Patent Claims:	see list of patent claims

Details for Patent 7,767,429

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004	⤷ Sign Up	2039-09-22
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004	⤷ Sign Up	2039-09-22
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004	⤷ Sign Up	2039-09-22
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005	⤷ Sign Up	2039-09-22
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859	December 02, 2005	⤷ Sign Up	2039-09-22
Merck Sharp & Dohme Llc	ZOSTAVAX	zoster vaccine live	For Injection	125123	May 25, 2006	⤷ Sign Up	2039-09-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,767,429

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Austria	E448323	⤷ Sign Up
Australia	2004218354	⤷ Sign Up
Australia	2006216545	⤷ Sign Up
Australia	2009245838	⤷ Sign Up
Australia	2013202475	⤷ Sign Up
Brazil	PI0408116	⤷ Sign Up
Brazil	PI0608314	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.